Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) FCF Margin (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of FCF Margin data on record, last reported at 23.7% in Q3 2025.

  • For Q3 2025, FCF Margin fell 4499.0% year-over-year to 23.7%; the TTM value through Sep 2025 reached 19.64%, down 3610.0%, while the annual FY2024 figure was 13.84%, 1679.0% up from the prior year.
  • FCF Margin reached 23.7% in Q3 2025 per PLX's latest filing, up from 36.17% in the prior quarter.
  • Across five years, FCF Margin topped out at 107.84% in Q1 2024 and bottomed at 90.28% in Q1 2021.
  • Average FCF Margin over 5 years is 17.93%, with a median of 27.14% recorded in 2022.
  • Peak YoY movement for FCF Margin: surged 17039bps in 2021, then tumbled -18251bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 64.74% in 2021, then surged by 58bps to 27.14% in 2022, then skyrocketed by 214bps to 30.84% in 2023, then crashed by -45bps to 17.08% in 2024, then crashed by -239bps to 23.7% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 23.7% in Q3 2025, 36.17% in Q2 2025, and 53.04% in Q1 2025.